Drug Delivery Platforms
•230 stocks
•
Total Market Cap: Loading...
Feb 06, 2026
|
AptarGroup Reports Q4 2025 Earnings: Revenue Beats, Margin Compression, and Cautious Q1 2026 Outlook
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (230)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Drug delivery platforms are highlighted as differentiators enabling scaled manufacturing.
|
$966.18B |
$1047.05
+2.57%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Drug delivery platform concepts (e.g., formulation/formulation technologies) are implied by delivery enhancements.
|
$80.57B |
$782.36
+2.05%
|
|
BDX
Becton, Dickinson and Company
BD develops drug delivery platforms and related biologic‑delivery solutions for therapeutics including GLP‑1s and wearables.
|
$59.19B |
$206.99
+0.23%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
ALNY employs drug delivery platforms (e.g., GalNAc conjugates) enabling targeted and durable RNAi delivery.
|
$43.42B |
$331.19
-0.02%
|
|
INSM
Insmed Incorporated
ARIKAYCE uses a liposomal inhalation drug-delivery platform (Pulmovance) and TPIP is an inhaled prodrug, making Drug Delivery Platforms a core Insmed technology.
|
$31.92B |
$151.96
+0.62%
|
|
BNTX
BioNTech SE
Drug Delivery Platforms cover mRNA delivery and related platforms used to deploy therapies.
|
$25.37B |
$106.82
+1.21%
|
|
PODD
Insulet Corporation
The insulin delivery platform functions as a drug delivery platform enabled by a medical device.
|
$17.12B |
$242.61
-0.22%
|
|
ASND
Ascendis Pharma A/S
TransCon is a proprietary drug-delivery platform enabling long-acting formulations, aligning with Drug Delivery Platforms.
|
$13.16B |
$222.71
+2.45%
|
|
JAZZ
Jazz Pharmaceuticals plc
Jazz's low-sodium formulation (Xywav) reflects a Drug Delivery Platform approach.
|
$9.90B |
$166.05
+1.78%
|
|
RNA
Avidity Biosciences, Inc.
Drug Delivery Platforms: AOC platform is a delivery technology for targeting oligonucleotides to specific tissues.
|
$9.37B |
$72.89
+0.10%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$9.17B |
$80.80
+3.03%
|
|
AXSM
Axsome Therapeutics, Inc.
MoSEIC drug-delivery platform powering Symbravo indicates reliance on Drug Delivery Platforms.
|
$9.02B |
$182.57
+0.96%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
TRiM is a drug delivery platform enabling targeted siRNA delivery beyond the liver.
|
$8.94B |
$65.71
+1.66%
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.17B |
$133.31
+7.52%
|
|
KRYS
Krystal Biotech, Inc.
Krystal's HSV-1 platform functions as a drug-delivery platform enabling redosable gene therapies across organs.
|
$7.75B |
$268.71
+0.40%
|
|
MTSR
Metsera, Inc.
HALO and MOMENTUM are proprietary drug-delivery platforms enabling extended half-life and oral peptide delivery, i.e., Drug Delivery Platforms.
|
$7.41B |
$70.53
+0.04%
|
|
GKOS
Glaukos Corporation
iDose TR represents a drug delivery platform delivering a sustained intraocular Travoprost formulation.
|
$6.51B |
$112.55
-0.85%
|
|
CDTX
Cidara Therapeutics, Inc.
Cloudbreak is a drug delivery platform (Drug-Fc Conjugate) enabling extended half-life and targeted activity.
|
$5.61B |
$221.39
+0.00%
|
|
ALKS
Alkermes plc
Proprietary drug delivery platforms (e.g., LinkeRx, NanoCrystal) used to create extended-release and rapid-dissolution formulations.
|
$5.54B |
$34.53
+2.94%
|
|
PTGX
Protagonist Therapeutics, Inc.
Platform-based drug delivery approach enabling peptide therapeutics.
|
$5.02B |
$84.06
+4.20%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Amneal's focus on drug delivery platforms spans multiple complex dosage forms and delivery technologies.
|
$4.64B |
$14.69
-0.58%
|
|
AKRO
Akero Therapeutics, Inc.
EFX is a biologic drug with a specialized delivery formulation (pre-filled syringe/lyophilized product), placing it squarely in the Drug Delivery Platforms category.
|
$4.37B |
$54.67
+0.04%
|
|
INDV
Indivior Pharmaceuticals Inc
SUBLOCADE's extended-release delivery represents a drug delivery platform (monthly dosing), a core investable theme.
|
$4.30B |
$34.30
-0.44%
|
|
STVN
Stevanato Group S.p.A.
Provides Drug Delivery Platforms as integrated containment and delivery solutions for biologics.
|
$4.29B |
$15.11
+6.78%
|
|
SRRK
Scholar Rock Holding Corporation
Drug Delivery Platforms: platform-based approach enabling targeted modulation of growth factor signaling via antibodies.
|
$4.27B |
$47.77
+7.47%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics' NDC platform and drug-conjugate strategy reflect a drug-delivery platform providing targeted payload delivery.
|
$4.22B |
$44.00
-1.76%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Captisol and NITRICIL are platform technologies Ligand licenses/sells to enable drug solubility and tunable dosing, constituting drug delivery platforms.
|
$3.76B |
$192.69
+0.52%
|
|
LQDA
Liquidia Corporation
Liquidia's YUTREPIA is a PRINT-enabled inhaled treprostinil, a drug-delivery platform that enables high-dose, deep-lung delivery and differentiated pharmacokinetics.
|
$3.58B |
$43.27
+4.11%
|
|
DNLI
Denali Therapeutics Inc.
The TransportVehicle platform is a drug delivery platform designed to cross the blood-brain barrier to deliver biologics to the CNS.
|
$2.93B |
$20.91
+4.47%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus leverages proprietary drug-delivery platforms, notably extended-release formulations, as a core differentiator for its CNS therapies.
|
$2.77B |
$51.15
+3.60%
|
|
BEAM
Beam Therapeutics Inc.
Beam uses lipid nanoparticle (LNP) delivery for in vivo base editing (BEAM-302, BEAM-301), i.e., a Drug Delivery Platform.
|
$2.50B |
$26.21
+5.98%
|
|
DYN
Dyne Therapeutics, Inc.
Dyne's FORCE platform is a drug delivery platform enabling targeted payload delivery to muscle and CNS, making it a core product category.
|
$2.35B |
$16.50
-0.30%
|
|
ETNB
89bio, Inc.
The company relies on a glycoPEGylation-based drug delivery platform to extend half-life and dosing convenience, representing a Drug Delivery Platforms investable theme.
|
$2.17B |
$14.85
+0.07%
|
|
SLNO
Soleno Therapeutics, Inc.
Drug Delivery Platforms reflects VYKAT XR's extended-release formulation and dosing advantage.
|
$2.10B |
$40.37
+2.00%
|
|
AVDL
Avadel Pharmaceuticals plc
Avadel uses a proprietary polymer-based extended-release drug-delivery platform to create once-nightly LUMRYZ.
|
$2.10B |
$21.64
+0.16%
|
|
IMNM
Immunome, Inc.
HC74 payload and linker optimization reflect a drug delivery platform approach.
|
$2.09B |
$24.82
+3.44%
|
|
WVE
Wave Life Sciences Ltd.
PRISM delivers oligonucleotides via conjugates (e.g., GalNAc) and non-viral delivery, constituting a drug delivery platform.
|
$2.03B |
$13.35
+4.71%
|
|
NUVB
Nuvation Bio Inc.
NUV-1511 is based on a Drug-Delivery Platform (DDC), directly describing a drug delivery platform product.
|
$1.92B |
$5.81
+3.38%
|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$1.90B |
$9.03
+1.35%
|
|
ANIP
ANI Pharmaceuticals, Inc.
Development of drug delivery platforms (e.g., Cortrophin Gel pre-filled syringe) demonstrates ANI's drug delivery technology differentiators.
|
$1.77B |
$80.75
-0.92%
|
|
SRPT
Sarepta Therapeutics, Inc.
Drug Delivery Platforms underpin Sarepta's delivery of gene therapies and RNAi assets.
|
$1.66B |
$18.34
+7.69%
|
|
ZYME
Zymeworks Inc.
Drug Delivery Platforms underpin ADC and multispecific payload engineering and delivery.
|
$1.66B |
$22.43
+1.86%
|
|
OCS
Oculis Holding AG
OPTIREACH is a drug delivery platform enabling topical therapies to reach the posterior segment.
|
$1.53B |
$27.90
+1.49%
|
|
CLDX
Celldex Therapeutics, Inc.
Drug delivery platforms and subcutaneous formulations are part of Celldex's formulation strategy.
|
$1.50B |
$23.03
+1.99%
|
|
PHVS
Pharvaris N.V.
Pharvaris emphasizes oral delivery with injectable-like efficacy, indicating a Drug Delivery Platforms orientation.
|
$1.38B |
$25.98
+3.36%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Drug Delivery Platforms captures Amphastar's proprietary delivery systems for injectables, inhalation, and intranasal therapies.
|
$1.33B |
$29.25
+2.17%
|
|
NVAX
Novavax, Inc.
Matrix-M is a proprietary vaccine adjuvant/drug-delivery platform used across Novavax's vaccine programs, constituting a major platform technology.
|
$1.28B |
$8.09
+2.73%
|
|
PGEN
Precigen, Inc.
Drug Delivery Platforms tag applies to platform-based delivery mechanisms like AdenoVerse and UltraCAR-T.
|
$1.26B |
$4.33
+2.00%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MindMed's use of a proprietary oral-dispensing drug-delivery technology constitutes a Drug Delivery Platform.
|
$1.24B |
$16.63
+2305.61%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX is using a drug delivery platform (PEP) to extend action of peptides, enabling less frequent dosing, fitting Drug Delivery Platforms.
|
$1.21B |
$37.81
+4.88%
|
|
NTLA
Intellia Therapeutics, Inc.
Proprietary drug-delivery platform (LNP) enabling in vivo gene editing across programs.
|
$1.19B |
$12.12
+9.29%
|
|
INBX
Inhibrx Biosciences, Inc.
Drug delivery platform technology underpinning biologic therapies.
|
$1.18B |
$81.96
+0.53%
|
|
BHVN
Biohaven Ltd.
MoDE/TRAP and related platforms constitute drug-delivery platforms enabling targeted degradation of extracellular proteins.
|
$1.14B |
$11.43
+6.18%
|
|
XERS
Xeris Biopharma Holdings, Inc.
Xeris's XeriSol and XeriJect drug-delivery platforms enable stable, ready-to-use injectable formulations, a core differentiator.
|
$1.12B |
$7.00
+1.37%
|
|
KOD
Kodiak Sciences Inc.
ABC/ABCD platforms are drug delivery technologies enabling sustained ocular release and extended durability.
|
$1.11B |
$22.85
+8.76%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$1.10B |
$11.36
+1.88%
|
|
CAPR
Capricor Therapeutics, Inc.
StealthX is described as an exosome-based drug delivery platform for targeted cargo delivery.
|
$1.05B |
$24.97
+8.42%
|
|
CVAC
CureVac N.V.
Drug Delivery Platforms captures CureVac's proprietary LNP delivery systems and thermostable formulations integral to its mRNA programs.
|
$1.05B |
$4.66
|
|
SVRA
Savara Inc.
Delivery via inhalation (Drug Delivery Platform) is a core aspect of MOLBREEVI's administration method.
|
$1.00B |
$5.58
-3.79%
|
|
NBTX
Nanobiotix S.A.
Curadigm and Oocuity are nanoparticle-based platforms aimed at drug delivery and neurally targeted effects, aligning with Drug Delivery Platforms.
|
$997.39M |
$21.51
+2.28%
|
|
VERV
Verve Therapeutics, Inc.
Verve's platform GalNAc-LNP is a proprietary drug delivery system used to target liver cells for gene-editing therapies.
|
$988.30M |
$11.13
|
|
TBPH
Theravance Biopharma, Inc.
YUPELRI's nebulized delivery represents a drug delivery platform differentiator for a respiratory therapy.
|
$986.07M |
$20.03
+2.30%
|
|
OPK
OPKO Health, Inc.
Entera Bio collaboration for oral formulation indicates an emphasis on drug delivery platforms.
|
$976.35M |
$1.24
+0.81%
|
|
VIR
Vir Biotechnology, Inc.
PRO-XTEN masking platform represents a drug delivery platform intended to improve safety and therapeutic index.
|
$961.30M |
$7.25
+4.84%
|
|
URGN
UroGen Pharma Ltd.
RTGel is a drug-delivery platform used by UroGen for localized, extended-release therapy.
|
$949.34M |
$21.31
+3.85%
|
|
ABUS
Arbutus Biopharma Corporation
Their LNP delivery technology is a drug delivery platform underpinning their RNAi assets.
|
$948.91M |
$4.58
-7.58%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$919.51M |
$4.16
-3.03%
|
|
PCRX
Pacira BioSciences, Inc.
Pacira's pMVL-based Drug Delivery Platforms enable extended-release formulations used in EXPAREL and ZILRETTA.
|
$914.83M |
$20.77
+1.99%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
Phathom is pursuing an orally disintegrating tablet (ODT) formulation and other delivery innovations for VOQUEZNA, aligning with the drug delivery platforms investable theme.
|
$880.41M |
$12.73
+2.58%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Core platform technology (Durasert E) used for sustained ocular drug delivery.
|
$877.45M |
$13.06
+2.63%
|
|
CTMX
CytomX Therapeutics, Inc.
PROBODY is a drug delivery platform designed to localize activity to tumors, fitting Drug Delivery Platforms.
|
$864.14M |
$5.62
+7.35%
|
|
GHRS
GH Research PLC
GH Research employs an inhalable drug delivery approach for GH001, representing a Drug Delivery Platforms capability.
|
$847.32M |
$15.06
+10.29%
|
|
PVLA
Palvella Therapeutics, Inc.
QTORIN represents a drug delivery platform for localized, topical therapy, a major category in pharmaceutical technology and patient-specific treatments.
|
$845.29M |
$82.20
+7.55%
|
|
FLGT
Fulgent Genetics, Inc.
Drug delivery platforms including nanoencapsulation.
|
$725.74M |
$23.51
-0.84%
|
|
NKTR
Nektar Therapeutics
PEGylation is a drug-delivery platform approach used to optimize pharmacokinetics and dosing.
|
$667.93M |
$36.95
+5.21%
|
|
SRDX
Surmodics, Inc.
The company provides proprietary drug-delivery platform technologies used on medical devices (SurVeil DCB) and related platforms.
|
$614.58M |
$42.98
|
|
HYEX
Healthy Extracts Inc.
Exclusive rights to an oral delivery technology for nutritional supplements, a distinctive platform that differentiates the company’s product delivery.
|
$611.57M |
$2.25
|
|
MGTX
MeiraGTx Holdings plc
Riboswitch platform represents a drug delivery platform enabling regulated transgene expression, a core technology.
|
$607.38M |
$7.40
-1.99%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$587.89M |
$21.00
-2.14%
|
|
KE
Kimball Electronics, Inc.
Drug delivery platforms are a targeted medical technology offering within KE's Medical CMO scope.
|
$573.17M |
$26.40
+12.10%
|
|
DSGN
Design Therapeutics, Inc.
GeneTAC platform implies a drug delivery/modulation approach, aligning with a Drug Delivery Platforms category.
|
$566.63M |
$10.24
+2.96%
|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$553.67M |
$2.31
-4.93%
|
|
REPL
Replimune Group, Inc.
RPx platform functions as a drug delivery platform enabling multi-gene payload immunotherapies.
|
$543.61M |
$7.49
+8.08%
|
|
RGNX
REGENXBIO Inc.
NAV platform involves drug delivery platform technology.
|
$518.28M |
$10.47
+2.05%
|
|
ZVRA
Zevra Therapeutics, Inc.
LAT platform enables prodrug drug delivery platforms, representing a proprietary drug-delivery platform technology.
|
$466.48M |
$8.48
+2.05%
|
|
ENGN
enGene Holdings Inc.
DDX platform is a drug delivery technology enabling localized genetic medicines, a distinct product category.
|
$453.56M |
$9.25
+4.40%
|
|
PRTC
PureTech Health plc
Glyph platform is a drug-delivery technology enabling oral administration of therapies.
|
$442.93M |
$18.98
+2.59%
|
|
ADCT
ADC Therapeutics S.A.
ADCT emphasizes a proprietary Drug Delivery Platform powering its ADC payloads and conjugation chemistries.
|
$439.87M |
$4.05
+3.71%
|
|
PRME
Prime Medicine, Inc.
Leverages a drug delivery platform (universal liver LNP with GalNAc targeting) to enable in vivo gene editing.
|
$436.02M |
$3.52
+8.80%
|
|
CYBN
Cybin Inc.
CYB004 utilizes a deuterated drug delivery approach including an inhalation platform, indicating a Drug Delivery Platforms capability.
|
$413.12M |
$8.30
+1.53%
|
|
AURA
Aura Biosciences, Inc.
Aura's VDC platform is a drug delivery platform enabling targeted, light-activated therapy.
|
$393.22M |
$6.16
-2.69%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT's Therapeutic Vector Evolution platform constitutes a drug delivery platform enabling targeted, durable gene therapy delivery.
|
$391.83M |
$8.80
+4.89%
|
|
DMAC
DiaMedica Therapeutics Inc.
DM199 represents a drug-delivery/therapeutic platform with IV administration and ongoing manufacturing development.
|
$389.73M |
$8.00
+6.10%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage emphasizes a drug delivery platform and formulation (cryopreserved thaw-and-inject formulations) enabling scalable, ready-to-administer cell therapies.
|
$383.64M |
$1.72
+2.38%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$383.03M |
$10.39
+3.18%
|
|
AQST
Aquestive Therapeutics, Inc.
Aquestive's PharmFilm drug-delivery platform enables non-invasive, thin-film administration of complex molecules; Anaphylm and Libervant employ this platform.
|
$382.94M |
$4.08
+6.38%
|
|
ANRO
Alto Neuroscience, Inc.
Drug delivery platform to enable targeted or improved administration of Alto's CNS therapeutics (e.g., transdermal PDE4 inhibitor).
|
$382.05M |
$14.95
+5.95%
|
|
MNPR
Monopar Therapeutics Inc.
MNPR-101 platform represents a drug delivery platform for radiopharmaceuticals, enabling targeted delivery and radionuclide conjugation.
|
$380.87M |
$56.59
-8.33%
|
|
LXEO
Lexeo Therapeutics, Inc. Common Stock
Uses a drug delivery platform (AAV vectors) to deliver genes, constituting a drug delivery platform business line.
|
$372.07M |
$7.16
+3.92%
|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$370.02M |
$7.32
+0.48%
|
Showing page 1 of 3 (230 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
